Broncus Holding Company Closes $10M Series D Financing

(VCBeat) Jan. 28, 2021 -- Broncus Holding Company ("Broncus"), a Hangzhou, China-based global leader in precise diagnosis with intervention for lung diseases, closed a Series D round of funding worth tens of millions of dollars. This round was led by FountainVest Partners, with participation from Exome Asset Management, Summer Capital, Valliance Capital, and others.

Broncus is a global leader focusing on the R&D of products for the diagnosis and therapy for lung diseases. Based on the world's only patented technology of real-time navigation and total lung access to nodules, Broncus has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending based on AI and algorithm, covering from diagnosis to treatment.

 The funding will be used for the R&D and upgrading, clinical trials, and global marketing of Broncus' core products for lung cancer, interventional therapy in emphysema, to develop the integrated solutions from interventional diagnosis to treatments based on the total lung navigation.

Broncus has previously raised three rounds of financing from Qiming Venture Capital, Lake Bleu Capital, Baidu Capital, Ascendum Capital, DCP Capital, Intuitive Surgical and other world-renowned venture capital firms and industrial giants.

Broncus has won nearly 200 patents worldwide. Its unique technology of Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA) meets the demand for high accuracy of total lung access in clinical, which makes up for the shortcomings of existing methods and treatment with low diagnostic rate, and opens up a new chapter in the precise positioning and diagnosis of the peripheral lesion.

FountainVest is a private equity fund dedicated to completely China. They seek to invest in industry leaders and emerging leaders with a strong track record delivering high growth. The company has completed a series of successful investments in Asia, Europe and the United States, focusing on consumer, media and technology, healthcare, industrial and financial services.

Founded in 2018 by Samuel D. Isaly, Exome Asset Management is an innovative asset management company focused on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biopharmaceuticals, healthcare services, and medical devices.